Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia
TREMFYA® long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
RYBREVANT FASPRO plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
